

Haematologica
HAEMATOL/2018/194571
Version 3

Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A

Jennifer E Adair, Devikha Chandrasekaran, Gabriella Sghia-Hughes, Kevin G Haworth, Ann E Woolfrey, Lauri M Burroughs, Grace Y Choi, Pamela S Becker, and Hans-Peter Kiem

Disclosures: This work was primarily funded by a Sponsored Research Agreement between Fred Hutch and Rocket Pharmaceuticals. J.E.A. and H.-P.K. are co-inventors on U.S. Provisional Patent Applications #62/491,116 and #62/503,801 "Novel Manufacturing of Gene Corrected Autologous Blood Cells for Gene Therapy." H.-P.K. and J.E.A. are consultants for Rocket Pharmaceuticals. The other authors declare that they have no competing interests.

Contributions: J.E.A. and H.-P.K. designed the study. J.E.A. and D.C. developed the lineage depletion protocol. J.E.A., D.C., and G.S.-H. performed lineage depletion experiments and data analysis. K.H. performed and analyzed mouse experiments. P.S.B. is the Principal Investigator of the clinical trial. G.Y.C. is the regulatory administrator for the clinical trial. P.S.B., A.W., and L.B. enrolled and attended patients on the clinical trial. J.E.A., D.C., and K.H. generated the figures. H.-P.K. and J.E.A. funded the study. J.E.A., D.C., and H.-P.K. wrote the manuscript. All authors reviewed and edited the final manuscript.